Country Information


Cote d'Ivoire
 
HIV prevalence 15-49, 2007/2008 3.9%
Tuberculosis death rate 105/100,000 population
Malaria death rate (children under 5) 438/100,000 population
 
   
             
     
  Cote d'Ivoire is a nation on the coast of West Africa with a population of about 17 million, and an HIV prevalence rate around 10 percent in the 15-49 age range. It is the world's leading producer of cocoa and is more prosperous than other leading West African nations such as Ghana or Nigeria. Donor nations considered Cote d'Ivoire to be one of the most politically stable sub-Saharan nations. This view changed overnight when an army mutiny and attempted coup in October 2002 led to fighting and the evacuation of French and American nationals. Rebels continue to occupy much of northern Cote d'Ivoire, and IRIN has reported that HIV infection rates have skyrocketed in the rebel-held areas.

Cote d'Ivoire was one of the first sub-Saharan nations to reach an agreement with major western pharmaceutical companies to provide antiretroviral medications at discounted rates. And its President, Laurent Gbagbo, has made a political commitment to fight HIV/AIDS, including making the head of the National Fight Against AIDS a member of his cabinet.

Continued political commitment will be needed, as Cote d'Ivoire's health crisis is daunting. According to a UNAIDS study, even if the transmission of HIV is halved over the next fifteen years, 25 percent of today's fifteen year-old boys in the country will die of AIDS.

Other troubles cloud the horizon as well: 47 percent of TB patients in Cote d'Ivoire are HIV positive, and sporadic use of antiretrovirals raises the possibility of resistant strains of HIV. Malaria also is endemic year-round throughout the country. MIM/TDR sponsored studies of the mosquito population in Cote d'Ivoire show that 80-90 percent of mosquitoes are developing resistance to pyrethroid, a common anti-malarial insecticide used in treated bednets. Still, bednets continue to be the most effective way to prevent malaria among children.

Sources: IRINnews, January 27, 2004; Washington Post, June 12, 2001; CDC Global AIDS Program; PubMed abstract: article on pyrethroid resistance

 
           
             
  Cote d'Ivoire's National AIDS Control Program is concentrating its efforts on reducing the spread of disease among youth, women, sex workers and migrant workers. The government budgeted 12 billion CFA francs (a little over $1.7 million) to implement its AIDS control program in 2001-2002. It has conducted major information and awareness campaigns, including a 2001 campaign closely associated with Cote d'Ivoire's First Lady, and a 2002 campaign focusing on the role of local government officials and NGOs. Cote d'Ivoire has worked with Nigeria, Ghana and Benin to establish a regional corridor against AIDS through improved border controls. Cote d'Ivoire is also one of 13 nations taking part in the UNAIDS Accelerating Access Initiative (AAI), allowing it to purchase HIV/AIDS drugs from pharmaceutical companies at reduced prices.

WHO estimates that 63 percent of TB cases in Cote d'Ivoire are detected and cured under DOTS.

Sources: AEGIS: Panafrican News Agency, June 6, 2001, AEGIS: Panafrican News Agency, November 10, 2001, AEGIS: Panafrican News Agency, January 15, 2002, AEGIS: Panafrican News Agency, July 30, 2001, CDC, United Nations Statistical Division

 
           
             
 
Total population. mid-2009 21.4 (millions)
HIV prevalence 15-49, 2007/2008 3.9%
Tuberculosis death rate 105/100,000 population
Prevalence of tuberculosis per 100,000 population, 2000 592
Prevalence of tuberculosis per 100,000 population, 2004 651
% Tuberculosis detection rate under DOTS, 2001 10
% Tuberculosis detection rate under DOTS, 2004 39
% Tuberculosis treatment success rate under DOTS, 2003 73
Malaria death rate (children under 5) 438/100,000 population
GNI PPP Per Capita, 2008 1,580 (US$)
Life expectancy at birth 52 years
Infant mortality rate 100/1,000 live births
Total fertility rate 4.9 per woman
Crude birth rate 37/1,000 population
Crude death rate 14/1,000 population
Adult male literacy level 70% (pct. 15+ literate)
Adult female literacy level 52% (pct. 15+ literate)
Contraceptive prevalence rate, modern methods 8% of women in union
Estimated number of people living with HIV: Adults and Children, 2005 750,000
Estimated number of people living with HIV: Adults and children, end 2003 570,000
Estimated number of people living with HIV: Adults and children, end 2001 510,000
Estimated number of people living with HIV: Adults (15+), 2005 680,000
Estimated number of people living with HIV: Adults (15-49), end 2003 530,000
Estimated number of people living with HIV: Adults (15-49), end 2001 480,000
Estimated number of people living with HIV: Adults (15-49) rate (%), 2005 7.0%
Estimated number of people living with HIV: Adults (15-49) rate (%), 2003 6.7%
Estimated number of people living with HIV: Women (15+), 2005 400,000
Estimated number of people living with HIV: Women 15-49, end 2003 300,000
Estimated number of people living with HIV: Women 15-49, end 2001 270,000
Estimated number of people living with HIV: Children (0-14), 2005 74,000
Estimated number of people living with HIV: Children (0-14), end 2003 40,000
Estimated number of people living with HIV: Children (0-14), end 2001 38,000
Estimated number of AIDS deaths: Adults and children, 2005 65,000
AIDS deaths in adults and children, end 2003 47,000
AIDS deaths in adults and children, end 2001 43,000
Estimated number of orphans due to AIDS: Children (0-17), 2005 450,000
Orphans due to AIDS (0-17), living 2003 310,000
Orphans due to AIDS (0-17), living 2001 270,000

Demographic data contained in this section was obtained from the following sources: The Population Reference Bureau’s 2009 World Population Data Sheet was used for total population, life expectancy at birth, infant mortality, fertility, birth rate, death rate, % of married women 15-49 using modern methods of contraception, % of population 15-49 with HIV/AIDS in 2007/2008, and the GNI PPP per capita (2008). Literacy rates were found in the Population Reference Bureau’s publication 2005 Women of Our World. HIV prevalence data for 2001 and 2003 was obtained from the UNAIDS Barcelona 2002 report; HIV prevalence and orphan data for 2005 was obtained from the UNAIDS Report on the Global AIDS Epidemic 2006. Data on the % women who have discussed AIDS prevention with their husband or partner can be found in ORC Macro and USAID’s Women’s Lives and Experiences: Changes in the Past Ten Years (Research Findings from the Demographic and Health Surveys). Childhood malaria mortality data was accessed in 2003 from the United Nations Statistics Divisions’ Millennium Indicators. Tuberculosis data was obtained from the United Nations Statistics Division’s Millennium Indicators: MDGInfo 2006. In some cases information was unavailable.

  
           
             
  Kassim Sidibe, the head of Cote d'Ivoire's National Fight Against AIDS, explained the inadequacies of his nation's health care infrastructure this way in a 2001 interview with a Washington Post reporter: "Health care access is a serious problem. There are no laboratories outside of Abidjan to administer and monitor necessary blood tests, and maybe 10 doctors in the country who know how to treat people with antiretrovirals. We have no follow-up capabilities. People don't get tested, so they don't know their HIV status." Developing Cote d'Ivoire's health infrastructure is a pressing need. During the 1990s about 4 percent of government spending was on healthcare.

Cote d' Ivoire has approximately 1,020 physicians (1990), 7,928 hospital beds (1993), 93 hospitals and 669 health centers. The largest hospital in the country is the 1,500 bed Treichville University Hospital in Abidjan. Perhaps half of the hospital beds in the country are now taken up by AIDS patients.

Sources: Washington Post, June 12, 2001; UNICEF.

 
           
             
 

OCCGE Institut Pierre Michet

Institut Pierre Michet has partnered with MIM/TDR in studying environmental factors in malaria transmission.

Universite de Abidjan-Cocody, UFR Sciences Medicales ( website )

Universite de Bouake, Faculty of Medicine ( website )

  
           
             
 

USAID closed its Cote d'Ivoire mission in FY 1998, although it has continued some activities through its West African Regional Family Health and AIDS Program.

Entity

Project Title

Diseases

Primary Category

Secondary Category
NIH DNA/MWA Immunogens, Cross-clade Immune Responses HIV/AIDS Drug Development  
  (Principal Investigator: Harriet Robinson. 2001-2006.) Professor Robinson of Emory University is investigating clade B immunogens in the United...

NIH Preclinical Trials HIV/AIDS Drug Development  
  (PI: ROBINSON, HARRIET L. 2001-2006.) An NIH grant to Emory University supporting the preclinical testing that will determine which DNAs or...

NIH NICHD Small Grants Program -- Perinatal HIV Transmission HIV/AIDS Epidemiology  
  (PI: Felix Aikhionbare. 2003-2005.) From the abstract: "This study is designed to understand the mutational role of HLA-G gene that make[s] HIV-1...

NIH AIDS International Training and Research Program HIV/AIDS Capacity  
  (PI: Arthur Reingold. 1998-2004.) A grant for the training of scientists and researchers from Cote d'Ivoire at the Fogarty International AIDS...

NIH Optimizing HIV Care in Less Developed Countries HIV/AIDS General  
  (P.I. FREEDBERG, KENNETH A., 2004-2008) The goal of this project is to help develop practical and affordable methods for HIV treatment and guide...

Other US CDC HIV/AIDS,Tuberculosis General  
  Cote d'Ivoire is a country participating in CDC's Global AIDS Program (GAP); CDC and Cote d'Ivoire have a partnership dating back to 1988. CDC...

International Tenofovir/Emtricitabine for PMTCT in Africa and Asia HIV/AIDS Drug Development Prevention
  French National Agency for Research on AIDS and Viral Hepatitits (Study Chair: François Dabis; Côte D’Ivoire PI: Didier Ekouevi). This Phase II...

International Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women: A Phase 3 Trial (UMA) HIV/AIDS Drug Development Prevention
  French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Merck, GlaxoSmithKline, Abbott (Study Chairs: Didier K Ekouevi,...

International Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire Malaria Drug Development  
  Sanofi-Aventis and Medicines for Malaria Venture. The primary outcome of this trial will focus on the polymerase chain reaction (PCR)-corrected and...

International Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-Infected Adults (ANRS 12136 TEMPRANO) HIV/AIDS,Tuberculosis Prevention Drug Development
  French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Merck (PIs: Xavier Anglaret, Serge Eholié). Participants in this...

International CIDA (Canada) HIV/AIDS Prevention  
  CIDA's AIDS 3 project in Cote d'Ivoire will concentrate on reducing the spread of HIV through commercial sex work.

Source: ...

International Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) HIV/AIDS,Tuberculosis General  
  In September 2003 the GFATM awarded an $18.1 million grant to fight HIV/AIDS to Cote d'Ivoire. The funds and program will be administered by the...

International World Bank Malaria General  
  In the spring of 2003 Cote d'Ivoire had about $12 million remaining on a $40 million World Bank Integrated Health Services Development Project. This...

NGO Bristol Myers Squibb: Secure the Future Programs HIV/AIDS General  
  In March, 2001, the Bristol Myers Squibb (BMS) Company, through Secure the Future, provided $15 million for...

Foundation Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) Antiretroviral Pregnancy Registry A Multi Site Protocol (APR) HIV/AIDS Drug Development  
  Elizabeth Glasser Pediatric AIDS Foundation (Study Director: Lulu Oguda; PIs: Richard Marlink, Joseph Kouakou, Perry Killam). This study will be...

Foundation Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients Malaria Drug Development  
  Medicines for Malaria Venture, Shin Poong Pharmaceuticals (Study Director: Claude Oeuvray; PIs: Alfred Tiono, Antoinette Tshefu Kitoto, Louis...

Foundation MTCT-Plus Initiative HIV/AIDS Prevention  
  The MTCT-Plus Initiative aims to prevent mother-to-child transmission of HIV in Cote d'Ivoire and several other developing nations with high...

 
           
             
  No information available  
           


Home || HIV/AIDS || Tuberculosis || Malaria || Advanced Search || Links || Contact Us

Last site update: December 08, 2009

For questions, or to report problems with this site, please contact the Webmaster.

Disclaimer